Skip to main content
SpringerLink
Log in

Aktuelle Möglichkeiten und Perspektiven der Liquoruntersuchung bei der Alzheimer Demenz

  • Conference paper
Alzheimer Demenz

  • 208 Accesses

Zusammenfassung

Die Liquoruntersuchung bei der Alzheimer Demenz (AD) dient traditionell zunächst zum differentialdiagnostischen Ausschluß überwiegend entzündlicher Erkrankungen, deren klinisches Bild sich in einem Demenzsyndrom manifestieren können. Alle chronisch verlaufenden Enzephalitiden können beispielsweise das Bild einer Demenz hervorrufen. Infektionskrankheiten mit Spirochäten (Neurolues und Lyme-Borreliose) und humanen Immundefizienzviren (HIV) sind weitere Beispiele für mögliche Einsatzgebiete der Liquoranalyse (Tabelle 9.1). Einen Sonderfall stellt u.a. der Normaldruckhydrozephalus dar, bei dem durch eine therapeutische Punktion bzw. Liquordrainage oft eine Verbesserung des klinischen Bildes innerhalb von Minuten bis Stunden erreicht werden kann.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Almkvist O, Basun H, Wagner SL, Rowe BA, Wahlund LO, Lannfelt L (1997) Cerebrospinal fluid levels of a-secretase-cleaved soluble amyloid precursor protein mirror Cognition in a Swedish family with Alzheimer’s disease. Arch Neurol 54: 641–644

    PubMed  CAS  Google Scholar 

  • Andreasen N, Vanmechelen E, Van de Voorde A et al. (1998) Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a Community based follow up study. J Neurol Neurosurg Psychiatry 64: 298–305

    Article  PubMed  CAS  Google Scholar 

  • Arai H, Morikawa Y, Higuchi M et al. (1997) Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. Biochem Biophys Res Commun 236: 262–264

    Article  PubMed  CAS  Google Scholar 

  • Arai H, Terajima M, Miura M, et al. (1995) Tau in cerebrospinal fluid: A potential diagnostic marker in Alzheimer’s disease. Ann Neurol 38: 649–652.

    Article  PubMed  CAS  Google Scholar 

  • Blennow K, Cowburn R, Wahlund LO, Winblad B (1998a) Der klinische Nutzen von Liquor-Markern bei der sporadischen Alzheimer-Krankheit. Alzheimer Insights 3: 4–7

    Google Scholar 

  • Blennow K, Davidsson P, Wallin A, Ekman R (1995b) Chromogranin A in cerebrospinal fluid: a biochemical marker for synaptic degeneration in Alzheimer’s disease?Dementia 6: 306–311

    PubMed  CAS  Google Scholar 

  • Blennow K, Vanmechelen E (1998b) Combination of the different biological markers for increasing specificity of in vivo Alzheimer’s testing. J Neural Transm Suppl. 53: 223–235

    PubMed  CAS  Google Scholar 

  • Blennow K, Wallin A, Agren H, Sprenger C, Siegfried J, Vanmechelen E (1995a) Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer’s disease?Mol Chem Neuropathol 26: 231–245

    Article  PubMed  CAS  Google Scholar 

  • Buch K, Riemenschneider M, Bartenstein P, Willoch F, Müller U, Schmolke M, Guder WG, Kurz A(1998) Tau-Protein: Ein potentieller biologischer Indikator zur Früherkennung der Alzheimer-Krankheit. Nervenarzt 69: 379–385

    Article  PubMed  CAS  Google Scholar 

  • Consensus Report of the Working Group on “Molecular and Biochemical Markers of Alzheimer’s Disease” (1998) Neurobiol Aging 19: 109-116

    Google Scholar 

  • Davidsson P, Jahn R, Bergquist J, Ekman R, Blennow K (1996) Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer’s disease?Mol Chem Neuropathol 27: 195–210

    Article  PubMed  CAS  Google Scholar 

  • Galasko D, Chang L, Motter R et al. (1998) High cerebrospinal fluid tau and low Amyloidß42 levels in the clinical diagnosis of Alzheimer’s disease and relation to ApolipoproteinE genotype. Arch Neurol 55: 937–945

    Article  PubMed  CAS  Google Scholar 

  • Galasko D, Clark C, Chang L, Miller B, Green RC, Motter R, Seubert P (1997) Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer’s disease. Neurology 48: 632–635

    PubMed  CAS  Google Scholar 

  • Hampel H, Kötter U (1997) Liquordiagnostik. In: Weis S, Weber G (Hrsg) Handbuch Morbus Alzheimer. Beltz Psychologie Verlags Union, Weinheim, pp 689–751

    Google Scholar 

  • Hampel H, Müller N(1995) Inflammatory and Immunological Mechanisms in Alzheimer’s Disease. Drug News and Perspectives 8 (10): 599–608

    Google Scholar 

  • Hampel H, Schoen D, Schwarz MJ et al. (1997a) Interleukin-6 is not altered in cerebrospinal fluid of firstdegree relatives and patients with Alzheimer’s disease. Neurosci Lett 228: 143–146

    Article  PubMed  CAS  Google Scholar 

  • Hampel H, Sunderland T, Padberg F, Kötter HU, Schneider C, Dukoff R, Levy J, Möller HJ(1998) Decreased soluble interleukin-6 receptor in CSF of patients with Alzheimer’s disease. Brain Res 780: 356–359

    Article  PubMed  CAS  Google Scholar 

  • Hampel H, Teipel SJ, Padberg F et al. (in press) Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer’s disease. Brain Res, in press

    Google Scholar 

  • Hock C, Golombowski S, Naser W, Müller-Spahn F(1995) Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer’s disease-correlation with degree of cognitive impairment. Ann Neurol 37: 414–415

    Article  PubMed  CAS  Google Scholar 

  • Jensen M, Basun H, Lannfelt L (1995) Increased cerebrospinal fluid tau in patients with Alzheimer’s disease. Neurosci Lett 186: 189–191

    Article  PubMed  CAS  Google Scholar 

  • Johnson GVW, Seubert P, Cox TM, Motter R, Brown JP, Galasko D (1997) The x protein in human cerebrospinal fluid in Alzheimer’s disease consists of proteolytically derived fragments. J Neurochem 68: 430–433

    Article  PubMed  CAS  Google Scholar 

  • Kanai M, Matsubara E, Isoe K et al. (1998) Longitudinal study of cerebrospinal fluid levels of tau, Aßl-40, and Aßl-42(43) in Alzheimer’s disease: a study in Japan. Ann Neurol 44: 17–26

    Article  PubMed  CAS  Google Scholar 

  • Kovanen J, Sulkava R (1986) Duration of postural headache after lumbar puncture: effect of needle size. Headache 26: 224–226

    Article  PubMed  CAS  Google Scholar 

  • Kurz A, Riemenschneider M, Buch K, Willoch F, Bartenstein P, Müller U, Guder W(1998) Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer’s disease. Alzheimer Dis Assoc Disord 12: 372–377

    Article  PubMed  CAS  Google Scholar 

  • Lannfelt L, Basun H, Wahlund LO, Rowe BA, Wagner SL (1995) Decreased a-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer’s disease. Nat Med 1: 829–832

    Article  PubMed  CAS  Google Scholar 

  • Linn RT, Wolf PA, Bachman DL, Knoefel JE, Cobb JL, Belanger AJ, Kaplan EF, D‘Agostino RB(1995) The “preclinical phase”of probable Alzheimer’s disease. Arch Neurol 52: 485–490

    PubMed  CAS  Google Scholar 

  • Mori H, Hosoda K, Matsubara E et al. (1995) Tau in cerebrospinal fluids: establishment of the Sandwich ELISA with an antibody specific to the repeat sequence in tau. Neurosci Lett 186: 181–183

    Article  PubMed  CAS  Google Scholar 

  • Motter R, Vigo-Pelfrey C, Kholodenko D et al. (1995) Reduction of ß-Amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann Neurol 38: 643–648

    Article  PubMed  CAS  Google Scholar 

  • Müller B, Adelt K, Reichmann H, Toyka K (1994) Atraumatic needle reduces the incidence of post-lumbar puncture Syndrome. J Neurol 241: 376–380

    Article  PubMed  Google Scholar 

  • Munroe WA, Southwick PC, Chang L, Scharre DW, Echols CL, Fu PC, Whaley JM, Wolfert RL (1995) Tau protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer’s disease. Ann Clin Lab Sei 25: 207–217

    CAS  Google Scholar 

  • Nitsch RM, Rebeck GW, Deng M et al. (1995) Cerebrospinal fluid levels of amyloid ß-protein in Alzheimer’s disease: Inverse correlation with severity of dementia and effect of apolipoprotein E genotype. Ann Neurol 37: 512–518

    Article  PubMed  CAS  Google Scholar 

  • Ohm TG, Müller H, Braak H, Bohl J(1995) Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer’s disease-related neurofibrillary changes. Neuroscience 164: 209–217

    Article  Google Scholar 

  • Pitschke M, Prior R, Haupt M, Riesner D (1998) Detection of Single amyloid ß-protein aggregates in the cerebrospinal fluid of Alzheimer’s patients by fluorescence correlation spectroscopy. Nat Med 4: 832–834

    Article  PubMed  CAS  Google Scholar 

  • Prior R, Monning U, Schreiter-Gasser U, Weidemann A, Blennow K, Gottfries CG, Masters CL, Beyreuther K (1991) Quantitative changes in the amyloid beta A4 precursor protein in Alzheimer cerebrospinal fluid. Neurosci Lett 124: 69–73

    Article  PubMed  CAS  Google Scholar 

  • Reiber H (1980) The discrimination between different blood-CSF-barrier dysfunetions and inflammatory reactions of the CNS by a recent evaluation graph for the protein profile of cerbrospinal fluid. J Neurol 224: 89–99.

    Article  PubMed  CAS  Google Scholar 

  • Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG (1996) Cerebrospinal protein tau is elevated in early Alzheimer’s disease. Neurosci Lett 212: 209–211

    Article  PubMed  CAS  Google Scholar 

  • Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG (1997) Diagnosis of Alzheimer’s disease with cerebrospinal fluid tau protein and aspartate aminotransferase. Lancet 350: 784

    Article  PubMed  CAS  Google Scholar 

  • Rösler N, Wichart I, Jellinger KA (1996) Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 60: 237–238

    Article  PubMed  Google Scholar 

  • Schlaf G, Salje C, Wetter A, Stuertz K, Felgenhauer K, Mader M (1998) Determinatio of synapsin I and synaptophysin in body fluids by two-site enzyme-linked immunosorbent assays. J Immunol Methods 213: 191–199

    Article  PubMed  CAS  Google Scholar 

  • Shoji M, Matsubara E, Kanai M et al. (1998) Combination assay of CSF tau, Aßl-40 and Aßl-42 (43) as a biochemical marker of Alzheimer’s disease. J Neurol Sei 158: 134–140

    Article  CAS  Google Scholar 

  • Skoog I, Vanmechelen E, Andreasson LA, Palmertz B, Davidsson P, Hesse C, Blennow K (1995) A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele. Neurodegeneration 4:433–442

    Article  PubMed  CAS  Google Scholar 

  • Strupp M, Brandt T (1997) Should one reinsert the stylet during lumbar puneture?N Engl J Med 336:1190

    Article  PubMed  CAS  Google Scholar 

  • Strupp M, Brandt T, Müller A(1998) Incidence of post-lumbar puneture Syndrome reduced by reinserting the stylet: A randomized prospective study of 600 patients. J Neurol 245: 589–592

    Article  PubMed  CAS  Google Scholar 

  • Tamaoka A, Sawamura N, Fukushima T et al. (1997) Amyloid beta protein 42(43) in cerebrospinal fluid of patients with Alzheimer’s disease. J Neurol Sei 148: 41–45

    Article  CAS  Google Scholar 

  • Tapiola T, Lehtovirta M, Pirttilä T, Alafuzoff I, Riekkinen P, Soininen H(1998) Increased aspartate aminotransferase activity in cerebrospinal fluid and Alzheimer’s disease. Lancet 352: 287

    Article  PubMed  CAS  Google Scholar 

  • Tato RA, Frank A, Hernanz A (1995) Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 59: 280–283

    Article  PubMed  CAS  Google Scholar 

  • Urakami K, Takahashi K, Saito H et al. (1992) Amyloid beta protein precursors with kunitz-type inhibitor domains and acetylcholinesterase in cerebrospinal fluid from patients with dementia of the Alzheimer type. Acta Neurol Scand 85: 343–346

    Article  PubMed  CAS  Google Scholar 

  • Van Nostrand WE, Wagner SL, Shankle WR et al. (1992) Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc Natl Acad Sei USA 89: 2551–2555

    Article  Google Scholar 

  • Vandermeeren M, Mercken M, Vanmechelen E, Six J, Van de Voorde A, Martin JJ, Cras P (1993) Detection of x proteins in normal and Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzymelinked immunosorbent assay. J Neurochem 61: 1828–1834

    Article  PubMed  CAS  Google Scholar 

  • Vigo-Pelfrey C, Seubert P, Barbour R et al. (1995) Elevation of microtubule-associated protein tau in the cerebrospinal fluid of patients with Alzheimer’s disease. Neurology 45: 788–793

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Harald Hampel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katharina Bürger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frank Padberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marcel Bahro
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik für Psychiatrie und Psychotherapie, der Technischen Universität München, Ismaninger Straße 22, 81675, München, Germany

    Hans Förstl

  2. Klinik und Poliklinik für Psychiatrie und Psychotherapie, der Technischen, Universität München, Arbeitsgruppe Epidemiologie, Klinikum rechts der Isar, Ismaninger Straße 22, 81675, München, Germany

    Horst Bickel

  3. der Klinik und Poliklinik für Psychiatrie und Psychotherapie der TU, Alzheimer Zentrum München, Möhlstraße 26, 81675, München, Germany

    Alexander Kurz

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Hampel, H., Bürger, K., Padberg, F., Bahro, M. (1999). Aktuelle Möglichkeiten und Perspektiven der Liquoruntersuchung bei der Alzheimer Demenz. In: Förstl, H., Bickel, H., Kurz, A. (eds) Alzheimer Demenz. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60228-3_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60228-3_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64313-2

  • Online ISBN: 978-3-642-60228-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation